Dermata therapeutics announces exercise of warrants for $2.66 million in gross proceeds priced at-the-market under nasdaq rules

San diego, ca / accesswire / may 17, 2024 / dermata therapeutics, inc. (nasdaq:drma)(nasdaq:drmaw) ("dermata," or the "company"), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 516,336 shares of the company's common stock, having exercise prices of $9.7665 and $32.40 per share, issued by dermata in november 2023 (with respect to 462,945 warrants) and may 2023 (with respect to 53,391 warrants), at a reduced exercise price of $5.16 per share. the shares of common stock issuable upon exercise of the warrants are registered pursuant to effective registration statements on form s-3 (file no.
NDAQ Ratings Summary
NDAQ Quant Ranking